CN1886123A - 具有肝功能保护作用的组合物 - Google Patents
具有肝功能保护作用的组合物 Download PDFInfo
- Publication number
- CN1886123A CN1886123A CNA2004800353794A CN200480035379A CN1886123A CN 1886123 A CN1886123 A CN 1886123A CN A2004800353794 A CNA2004800353794 A CN A2004800353794A CN 200480035379 A CN200480035379 A CN 200480035379A CN 1886123 A CN1886123 A CN 1886123A
- Authority
- CN
- China
- Prior art keywords
- liver function
- compositions
- protective effect
- described compositions
- coenzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 230000003908 liver function Effects 0.000 title claims abstract description 41
- 230000001681 protective effect Effects 0.000 title claims abstract description 25
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 109
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 101
- 239000000463 material Substances 0.000 claims description 21
- 210000004185 liver Anatomy 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical group COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 4
- 235000001497 healthy food Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 239000011669 selenium Substances 0.000 abstract description 11
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract description 9
- 229910052711 selenium Inorganic materials 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 35
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 35
- 229940035936 ubiquinone Drugs 0.000 description 35
- 235000014347 soups Nutrition 0.000 description 23
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 244000269722 Thea sinensis Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- -1 shaped Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 235000011649 selenium Nutrition 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 241000628997 Flos Species 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 235000010254 Jasminum officinale Nutrition 0.000 description 3
- 240000005385 Jasminum sambac Species 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241001529246 Platymiscium Species 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 240000004784 Cymbopogon citratus Species 0.000 description 2
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 241001251949 Xanthium sibiricum Species 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930003949 flavanone Natural products 0.000 description 2
- 150000002207 flavanone derivatives Chemical class 0.000 description 2
- 235000011981 flavanones Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008616 guibi-tang Substances 0.000 description 2
- 239000008563 guizhi decoction Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- NTNWKDHZTDQSST-UHFFFAOYSA-N naphthalene-1,2-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CC=C21 NTNWKDHZTDQSST-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- YKCSNTMMXNGKSJ-UHFFFAOYSA-N 2,2-dihydroxy-2-(methylamino)acetic acid Chemical compound CNC(O)(O)C(O)=O YKCSNTMMXNGKSJ-UHFFFAOYSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000000530 Alcea rosea Species 0.000 description 1
- 235000017334 Alcea rosea Nutrition 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 235000017303 Althaea rosea Nutrition 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 235000007258 Anthriscus cerefolium Nutrition 0.000 description 1
- 240000002022 Anthriscus cerefolium Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 description 1
- 101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- XZIXQCXPRYPHFJ-UHFFFAOYSA-N C(CCC)(C(=O)O)(C(=O)O)C(=O)O.P(O)(O)=O Chemical class C(CCC)(C(=O)O)(C(=O)O)C(=O)O.P(O)(O)=O XZIXQCXPRYPHFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000801434 Eruca Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 235000016970 Fragaria moschata Nutrition 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000014828 Fragaria vesca ssp. americana Nutrition 0.000 description 1
- 235000012660 Fragaria virginiana Nutrition 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 244000215562 Heliotropium arborescens Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 235000003001 Hyssopus Nutrition 0.000 description 1
- 241001529756 Hyssopus <angiosperm> Species 0.000 description 1
- 241000167847 Koelreuteria paniculata Species 0.000 description 1
- 241000729183 Lagopsis Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 241001442129 Myosotis Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 235000010679 Nepeta cataria Nutrition 0.000 description 1
- 240000009215 Nepeta cataria Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- PCTSMYBTOQYNDS-UHFFFAOYSA-N OC(C)C.NNC(=O)NN Chemical compound OC(C)C.NNC(=O)NN PCTSMYBTOQYNDS-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000011464 Pachycereus pringlei Nutrition 0.000 description 1
- 235000011466 Pachycereus weberi Nutrition 0.000 description 1
- 240000006939 Pachycereus weberi Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 241001019054 Parthenocissus vitacea Species 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- 244000295490 Salvia japonica Species 0.000 description 1
- 240000003946 Saponaria officinalis Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000009225 Stachys officinalis Nutrition 0.000 description 1
- 244000303286 Stachys officinalis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000907897 Tilia Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 240000000992 Trifolium incarnatum Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 235000010599 Verbascum thapsus Nutrition 0.000 description 1
- 244000178289 Verbascum thapsus Species 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 244000225942 Viola tricolor Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000009253 Xiexin decoction Substances 0.000 description 1
- BDBRARIQKQBCLD-UHFFFAOYSA-J [Na+].[Na+].[Na+].[Na+].C(=O)([O-])C(N(C)C(=O)[O-])(CCC(=O)[O-])C(=O)[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].C(=O)([O-])C(N(C)C(=O)[O-])(CCC(=O)[O-])C(=O)[O-] BDBRARIQKQBCLD-UHFFFAOYSA-J 0.000 description 1
- OJRVXKQRBBLYLI-UHFFFAOYSA-N [Se].C1=CC=CC2=C(N)C(N)=CC=C21 Chemical compound [Se].C1=CC=CC2=C(N)C(N)=CC=C21 OJRVXKQRBBLYLI-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000000183 arugula Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000010047 cheongseoikki-tang Substances 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008912 dachengqi decoction Substances 0.000 description 1
- 239000009362 danggui-shaoyao-san Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZDKZHVNKFOXMND-UHFFFAOYSA-N epinepetalactone Chemical compound O=C1OC=C(C)C2C1C(C)CC2 ZDKZHVNKFOXMND-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000009428 kamisyoyo san Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000008876 liujunzi Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 239000008473 mahuang fuzi xixin Substances 0.000 description 1
- 239000008692 maimendongtang Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000009799 maxingganshi Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- BDGIOFKLQPUORK-UHFFFAOYSA-N n-ethoxy-n-ethylethanamine Chemical compound CCON(CC)CC BDGIOFKLQPUORK-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 239000010243 sho-seiryu-to Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- MSXHSNHNTORCAW-GGLLEASOSA-M sodium;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O MSXHSNHNTORCAW-GGLLEASOSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000009396 suanzaoren Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000008423 tao-shang-tsao Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fodder In General (AREA)
Abstract
本发明提供对各种原因产生的肝功能损害都具有功能保护和损害预防作用并且安全性优异的组合物。本发明者发现,即使不含硒,氧化型辅酶Q也具有肝功能保护作用,另外,还原型辅酶Q具有更强的肝功能保护作用。通过使用以含硒量不足0.01重量%的氧化型辅酶Q或还原型辅酶Q为主要成分的组合物,可以保护肝功能。通过本发明,可以提供安全性高、并发挥优异的健康维持效果的组合物。
Description
技术领域
本发明涉及含有辅酶Q的具有肝功能保护作用的组合物。
背景技术
肝脏在生物体的化工厂中是具有例如生成胆汁,作为3大营养素的碳水化合物、蛋白质、脂肪的代谢调节·贮藏,废物或有害物质的分解·解毒,造血·血液量的调节等生物体不可缺少的多种多样的重要作用的重要脏器。病毒感染、酒精的过量摄取、药物中毒、饮食生活的紊乱、压力、吸烟等造成上述功能受到损害,以至于引起急性肝炎、慢性肝炎、酒精性脂肪肝、肝癌等疾病。
肝细胞受到病毒、酒精、药物等损害时,细胞中的谷草转氨酶(以下简称GOT)或谷丙转氨酶(以下简称为GPT)等酶会进入血液中,因此,血液中这些酶的活性上升。因此,血液中这些GOT、GPT活性通常广泛作为显示肝脏的功能损害的指标。
作为肝功能损害的预防或治疗中使用的药剂,已知抗病毒剂、免疫抑制剂、谷胱甘肽等。另外,作为对肝功能的保护·增强·改善有效的饮食,已知姜黄(ウコン)、芝麻素(セサミン)、玛利亚蓟(マリアアザミ)、芝麻木脂素(ゴマリグナン)等。
已知辅酶Q是广泛分布在从细菌到哺乳动物的生物体内的必需成分,并作为生物体内细胞中线粒体的电子传导系统构成成分而存在。辅酶Q在线粒体内通过反复进行氧化和还原而承担作为电子传导系统中的传导成分的功能,此外,还原型辅酶Q还显示出抗氧化作用。在人体中,辅酶Q的侧链上具有10个重复结构的辅酶Q10为主要成分。
作为辅酶Q10的重要特征,可以举出其安全性高这一事实。有报告(K.D.Williams,et al,J.Agric.Food Chem.,
47 3756-3763,1999)称:在对大鼠的慢性毒性试验中,即使以1200mg/Kg/日连日给药52周,完全没有毒性影响。1200mg/Kg换算为人体(50Kg)则为60g/日,作为保健食品在欧美使用的辅酶Q10的常用量为100~300mg/日,因此可以判定,辅酶Q10的安全性完全没有问题。
氧化型辅酶Q10在日本作为充血性心力衰竭药物,在欧美作为保健食品广泛使用。作为与辅酶Q10的肝功能保护相关的使用例,有以下报告:通过向大鼠进行氧化型辅酶Q10的腹腔内给药,对由四氯化碳引起的肝功能损害有抑制效果(T.Takahashi,et.al,Biol.Pharm.Bull.,
19 1005-1012,1996)、含有氧化型辅酶Q10和0.01~0.1重量%的硒而用于肝脏疾病的医药处方(特开平11-199477号公报)等,但是还不知道口服摄取实质上不含硒而含有氧化辅酶Q10的组合物时对肝功能损害的保护作用,以及通过摄取还原型辅酶Q10对肝功能损害的保护作用。
还原型辅酶Q10是氧化辅酶Q10被还原的物质,但由于在空气中容易受到氧化而转变为氧化型辅酶Q10,因此以往尚未制成产品使用。我们发现,与以往单独的氧化型辅酶Q10比较,通过混合还原型辅酶Q10,作为辅酶Q10总体的口服吸收性提高(特开平10-109933号公报),但是,关于肝功能保护作用,还原型辅酶Q10与氧化型辅酶Q10相比,是否显示出优异的效果尚不明确。
发明内容
本发明的目的在于,提供具有肝功能保护作用并且安全性优异的物质。
本发明者们为解决上述课题而进行研究的结果发现,即使不含硒,氧化型辅酶Q也具有肝功能保护作用,另外,还原型辅酶Q比氧化型辅酶Q具有更强的肝功能保护作用。
即,本发明涉及含有用下述式(1)(式中,n表示1~12的整数)表示的还原型辅酶Q的具有肝功能保护作用的组合物。
另一方面,本发明提供将上述还原性辅酶Q作为有效成分的肝功能保护剂。
另外,本发明涉及具有肝功能保护作用的组合物,该组合物是含有用下述式(2)(式中,n表示1~12的整数)表示的氧化型辅酶Q和硒的具有肝功能保护作用的组合物,该组合物中,硒的含量不足0.01重量%。
另一方面,本发明提供将氧化性辅酶Q作为有效成分的肝功能保护剂。
附图说明
图1是表示大鼠血浆中的GPT活性随时间变化的折线图。纵轴表示血浆中的GPT活性。横轴表示给予四氯化碳后经过的时间。数据表示溶剂对照组、还原型辅酶Q10(约含有2%的氧化型辅酶Q10)组、氧化型辅酶Q10组。以n=4的平均值±标准差表示。
具体实施方式
在本发明中,所谓肝功能的保护,是指保护肝功能不受各种损害的作用以及预防肝功能不受损害的作用。作为上述肝功能保护的例子,可以举出,例如,抑制由于四氯化碳的投放引起的血液中的GPT、GOT的活性的上升。
辅酶Q用下述式(1)(式中,n表示1~12的整数)、以及下述式(2)(式中,n表示1~12的整数)表示。
式(1)为还原型辅酶Q,式(2)为氧化型辅酶Q。作为获得氧化型辅酶Q和还原型辅酶Q的方法,没有特别的限定,可以采用例如,通过合成、发酵、从天然物质中提取等以往已知的方法,得到辅酶Q后,通过色谱法浓缩流出液中的氧化型辅酶Q组分(区分)或还原型辅酶Q组分的方法等。想要得到氧化型辅酶Q时,可以通过已知的方法得到(例如,参照特开昭53-38690号公报)。得到还原型辅酶Q时,可以视需要向上述氧化型辅酶Q中添加硼氢化钠、连二亚硫酸钠(连二亚硫酸钠)等通常的还原剂,通过常规方法还原上述氧化型辅酶Q,制成还原型辅酶Q之后,通过色谱法进行浓缩。另外,通过使现有的高纯度氧化型辅酶Q与上述还原剂作用的方法也可以得到还原型辅酶Q。
可以在本发明中使用的辅酶Q如上述式(1)和(2)表示,可以使用侧链的重复单元(式中n)为1~12的辅酶Q,其中,特别优选侧链重复单元为10的辅酶Q,即辅酶Q10。这是由于,在人体中,辅酶Q的侧链具有10重复结构的辅酶Q10是主要成分。
一方面,本发明的具有肝功能保护作用的组合物(以下称本发明的组合物)是含有还原型辅酶Q的组合物。另一方面,本发明的组合物是含有氧化型辅酶Q和硒并且硒的含量不足0.01重量%的组合物。
在本发明的含有还原型辅酶Q的组合物中,作为还原型辅酶Q的含量优选0.001~99重量%。更为优选0.01~20重量%。
本发明的含有氧化型辅酶Q和硒的组合物,在硒的含量不足0.01重量%的组合物中,作为氧化型辅酶Q的含量优选0.001~99重量%。更为优选0.01~20重量%。
含有还原型辅酶Q的组合物还可以含有氧化型辅酶Q。此时,还原型辅酶Q相对于辅酶Q全体的含量没有特别的限制,优选50重量%或50重量%以上,更加优选60重量%或60重量%以上,尤其优选70重量%或70重量%以上,特别优选80重量%或80重量%以上。
本发明的含有氧化型辅酶Q的组合物即使不含硒也具有肝功能保护作用。作为硒的含量,优选不足0.01重量%,更加优选不足0.001重量%。
硒的含量少或不含硒的组合物在由硒而给生物体带来的不良影响小这一点上是有利的。
组合物中的硒含量可以通过下示方法测定。将适量的试验材料采集到试管中,加入10ml的浓硝酸,在室温下放置一夜。将试管的温度徐徐升至130℃,使之产生茶色的气体,保持原来的温度直至液体量变为1ml。然后,将试管的温度恢复到室温,加入3ml的高氯酸。将试管的温度徐徐上升至150℃,则从二氧化氮的茶色气体变为高氯酸的白色气体,保持温度直至液体量变为1~2ml。然后,将试管温度恢复到室温,添加2ml的6N的盐酸。将其在130℃下处理1小时。向上述处理样品中加入6N的氨溶液,将pH调整至1~2。使之在50℃与0.1%的二氨基萘(DAN)溶液反应20分钟,用环己烷萃取。通过荧光分光分析(激发波长380nm、荧光波长520nm)对环己烷相中所含的硒-二氨基萘复合体进行测定,计算试验材料中的硒含量。
组合物中的还原型辅酶Q10和氧化型辅酶Q10的含量可以用下示方法测定。向试验材料50mg中依次加入水0.1ml、甲醇0.4ml、己烷0.6ml。将其激烈振荡约30秒,而后通过离心分离分离为两层。定容提取(定容量分取)有机溶剂层,使用氮气使之立即蒸发干固。向其中添加0.2ml的乙醇,制成定量分析用样品。还原型辅酶Q10和氧化型辅酶Q10的定量分析按照以下条件使用高速液相色谱仪实施。
柱:长25cm、直径4.6mm、YCM-PACK ODS-A(株式会社ワイエムシイ制造)
移动相:甲醇∶己烷(85∶15、v/v)
检测波长:290nm
流速:1.0ml/分
本发明的组合物可以使用于医药制剂、功能性食品、食品原材料、或者动物用饲料等。这里所说的功能性食品,是指口服补充剂(サプリメント)、特定保健用食品、保健食品、营养辅助食品等医药制品以外的通过口服摄取以维持或改善健康为目的的产品。
制作本发明的组合物时的辅酶Q的含量、剂型、保存方法以及保存形态可以根据医药制剂、保健食品、食品、动物用医药制品、动物用饲料等用途而适当决定。
作为含有本发明的组合物的医药制剂的剂型没有特别的限制,例如,可以是液体制剂,也可以是粉末剂,也可以添加粘合剂制成颗粒剂,可以用包衣剂将粉末包覆,还可以将粉末剂或颗粒剂或者包衣剂填充到胶囊中。作为上述液体制剂,没有特别的限制,可以举出,例如,饮剂(ドリンク剤)、注射剂、滴注剂(点滴用剤)等。另外,可以添加天然油、油状高级脂肪酸、高级脂肪酸单甘油酯、表面活性剂或它们的混合物等,直接以油状进行填充而制成软胶囊剂。此时,可以使用以明胶为主体的物质或以其他水溶性高分子物质为主体的物质等。另外,这样的胶囊中还可以还有微胶囊。
本发明的组合物或医药制品的给药形态可以是固体状的任意形态,给药方法可以使用通过口服、注射、滴注、栓剂给药、食用含有本发明的组合物的食品等各种方法。通常地,从摄取简便的观点来看,优选口服给药,但口服给药困难时,用口服以外例如注射等给药方法将本发明的组合物给药也没有任何问题。
本发明的组合物还可以在以往使用的具有肝功能保护作用的食品类中含有辅酶Q。
这些组合物中的含有还原型辅酶Q的肝功能保护用组合物中,优选为防止还原型辅酶Q氧化而添加抗氧化剂,但根据剂型也可以不添加。作为可以在此时使用的抗氧化剂,可以举出,柠檬酸、柠檬酸衍生物、维生素C、维生素C衍生物、番茄红素、维生素A、类胡萝卜素、维生素B、维生素B衍生物、类黄酮类、多酚类、谷胱甘肽、硒、硫代硫酸钠、维生素E、维生素E衍生物、超氧化物歧化酶(SOD)、谷胱甘肽过氧化酶、谷胱甘肽-S-转移酶、谷胱甘肽还原酶、过氧化氢酶、抗坏血酸超氧化物酶、以及它们的混合物。
这些组合物中的含有还原型辅酶Q的肝功能保护用组合物中,同样从防止氧化的观点来看,还可以使用螯合剂。作为可以在此时使用的螯合剂,可以举出,乙二胺四乙酸及其盐、乙二胺二乙酸及其盐、羟亚氨基二乙酸及其盐、羟乙基二乙胺四乙酸及其盐、二亚乙基三胺五乙酸及其盐、氮川三乙酸及其盐、三亚乙基四胺六乙酸及其盐、二羧基甲基谷氨酸四钠盐、二羟基甲基甘氨酸、1,3-丙二胺四乙酸及其盐、1,3-二氨基-2-羟基丙烷四乙酸及其盐、葡糖酸钠盐、ヒドロキシエチルイデンジホスホン酸、氨基三(ニトリロトリス)、膦酸基丁烷三羧酸、以及它们的混合物。另外,可以同时使用以上的抗氧剂和螯合剂。
还可以通过常规方法向本发明的组合物中添加上述辅酶Q以外的药剂学和食品卫生学上允许的其他的原料。作为这样的物质,没有特别的限定,可以举出,例如,赋形剂、崩解剂、润滑剂、粘合剂、包衣剂、着色剂、抗凝剂、吸收促进剂、助溶剂、稳定剂、保健食品原料、营养补充食品原料、维生素等。
作为上述赋形剂,没有特别的限制,可以举出,例如,白糖、乳糖、葡萄糖、玉米淀粉、甘露糖醇、结晶纤维素、磷酸钙、硫酸钙等。作为上述崩解剂,没有特别的限制,可以举出,例如,淀粉、琼脂、柠檬酸钙、碳酸钙、碳酸氢钠、糊精、结晶纤维素、羧甲基纤维素、西黄蓍胶等。作为上述润滑剂,没有特别的限定,可以举出,例如,滑石、硬脂酸镁、聚乙二醇、二氧化硅、固化植物油等。作为上述粘合剂,没有特别的限定,可以举出,例如,乙基纤维素、甲基纤维素、羟丙基甲基纤维素、西黄蓍胶、紫胶、明胶、阿拉伯树胶、聚乙烯吡咯烷酮、聚乙二醇、聚丙烯酸、聚甲基丙烯酸、山梨糖醇等。作为上述包衣剂,没有特别的限定,可以举出,阿拉伯树胶、オパドライ、夏枯草(カゴソウ)、カスタ一ワツクス、羧基乙烯基聚合物、カルメロ一ス、水合二氧化硅、硅酸镁、醋酸乙烯树脂、硬脂酸、鲸蜡醇、羟丙基甲基纤维素等。作为上述着色剂,没有特别的限定,可以使用例如可以添加在医药制品或食品中的物质。作为上述抗凝剂,没有特别的限制,可以举出,例如,硬脂酸、滑石、轻质硅酸酐、水合二氧化硅等。作为上述吸收促进剂,没有特别的限制,可以举出,例如,高级醇类、高级脂肪酸类、甘油脂肪酸酯等表面活性剂等。作为上述助溶剂,没有特别的限制,可以举出,例如,富马酸、琥珀酸、苹果酸等有机酸等。作为上述稳定剂,没有特别的限制,可以举出,例如,安息香酸、安息香酸钠、对羟基安息香酸乙酯等。作为上述保健食品原料,没有特别的限制,可以举出,具有肝功能保护作用的食品类(例如,黄烷酮二烯醇、姜黄、芝麻素、玛利亚蓟、芝麻木脂素等)、中药(例如:胃苓汤、温经汤、温清饮、黄耆建中汤、黄连解毒汤、黄连汤、葛根汤、加味归脾汤、加味逍遥散、甘麦大枣汤、桔梗汤、归脾汤、九味槟榔汤、荆芥连翘汤、桂皮加芍药大黄汤、桂皮加芍药汤、桂皮加龙骨牡蛎汤、桂枝汤、桂枝人参汤、桂枝茯苓丸、启脾汤、香苏散、五虎汤、五积散、牛车肾气丸、五淋散、柴陷汤、柴胡加龙骨牡蛎汤、柴胡桂皮干姜汤、柴胡桂枝汤、柴胡清肝汤、柴朴汤、柴苓汤、酸枣仁汤、滋阴降火汤、四逆散、四君子汤、四物汤、灸甘草汤、芍药甘草汤、十全大补汤、十味败毒汤、小建中汤、小柴胡汤、小青龙汤、消风散、辛夷清肺汤、神秘汤、真武汤、清上防风汤、清暑益气汤、清心莲子饮、清肺汤、疏经活血汤、大黄甘草汤、大黄牡丹皮汤、大建中汤、大柴胡汤、大柴胡汤去大黄、大承气汤、大防风汤、治大扑一方、调胃承气汤、钓藤散、肠痈汤、猪苓汤、猪苓汤合四物汤、通导散、桃核承气汤、当归饮子、当归建中汤、当归芍药散、当归汤、二陈汤、女神散、人参汤、人参营养汤、排浓散及汤、麦门冬汤、八味地黄丸、半夏厚朴汤、半夏泻心汤、白虎加人参汤、茯苓饮、茯苓饮合半夏厚朴汤、平胃散、防已黄耆汤、防风通圣散、补中益气汤、麻黄汤、麻黄附子细辛汤、麻杏甘石汤、麻子仁丸、木防已汤、抑肝散、抑肝散加陈皮半夏、六君子汤、立效散、龙胆泻肝汤、苓甘姜味辛夏仁汤、六味丸等)、茶叶(例如,绿茶、糙米茶、抹茶、煎茶、ほうじ茶、焙茶、茉莉花茶、乌龙茶、红茶、黑茶、花茶、青茶、白茶等)、药草(例如,意大利香菜(イタリアンパセリ)、土木香(エリキヤンペ一ン)、橄榄、薄荷属植物(オレガノ)、刺菜蓟(カ一ルドン)、春黄菊(カモミ一ル)、咖喱植物(カレ一プラント)、樟脑草(キヤツトニツプ)、藏茴香(キヤラウエイ)、圣诞蔷薇(クリスマスロ一ズ)、绛车轴草(クリムソンクロ一バ)、矢车菊(コ一ンフラワ一)、锦葵属植物(コモンマロウ)、サラダバ一ネツト、サントリナ、肉桂(シナモン)、茉莉(ジヤスミン)、斯特维亚菊(ステビア)、鼠尾草(セ一ジ)、椴树(セイヨウボダイジユ)、老鹳草(センデツトゼラニウム)、セントジヨ一ンズワ一ト、石硷草(ソ一プワ一ト)、ソロモンズシ一ル、百里香(タイム)、艾菊(タンジ一)、雪维菜(チヤ一ビル)、细香葱(チヤイブ)、金莲花(ナスタチウム)、枣、罗勒属植物(バジル)、忍冬属植物(ハニ一サツクル)、海索草属植物(ヒソツプ)、亚麻(フラツクス)、茴香(フエンネル)、毛地黄(フオツクスグロ一ブ)、黑蜀葵(ブラツクリ一ホ一リ一ホツク)、法国金盏花(フランチマリ一ゴ一ルド)、欧水苏(ベトニ一)、天芥菜(ヘリオトロ一プ)、香柠檬(ベルガモツト)、ヘンプアグリモニ一、芸香属植物(ヘンル一ダ)、盆栽金盏花(ポツトマリ一ゴ一ルド)、琉璃苣(ボリジ)、白夏至草(ホワイトホアハウンド)、桃金壤科植物(マ一トル)、毛蕊花属植物(マ一レイン)、茉乔栾那属植物(マジヨラム)、薄荷属植物(ミント)、西洋蓍草(ヤロウ)、熏衣草(ラベンダ一)、篷子菜植物(レデイ一スベツドストロ一)、柠檬草(レモングラス)、柠檬马鞭草(レモンバ一ベナ)、柠檬脂(レモンバ一ム)、玫瑰(ロ一ズ)、迷迭香(ロ一ズマリ一)、芝麻菜(ロケツト)、野草莓(ワイルドストロメリ一)、野三色紫罗兰(ワイルドパンジ一)、勿忘草属植物(忘れな草)等)、蜂胶(プロポリス)、银杏药(イチヨウ葉)、青汁(青汁)以及它们的提取物等。上述保健食品原材料优选具有肝功能保护作用的食品类,例如:黄烷酮二烯醇、姜黄、芝麻素、玛利亚蓟、芝麻木脂素等。作为上述营养补充食品原材料,没有特别的限制,可以举出,氨基酸类、金属离子类、蛋白质类、糖类、脂肪酸类、酵母提取物、蔬菜提取物、鱼肉提取物、果实、果实提取物等。上述作为维生素,没有特别的限制,可以举出,维生素A、维生素D、维生素E、维生素K、维生素B1、维生素B2、烟酰胺、维生素B6、叶酸、维生素B12、维生素H、泛酸、维生素C、吡咯并喹啉醌等。
通过适当使用本发明中得到组合物,可以有效地保护哺乳动物例如人类和动物的肝功能。
实施例
以下,列举实施例和制剂例,更为详细地说明本发明,但本发明并不是仅受这些实施例和制剂例的限定。
(实施例1)
使用由四氯化碳引起的肝功能损害的模型,评价辅酶Q10的损害保护以及预防效果。以100mg/kg的给药量向SD系大鼠(6周岁,雄性)口服给药氧化型辅酶Q10或还原型辅酶Q10(其中,含有约2%的氧化型辅酶Q10)的大豆油溶液。然后,约16小时后,从颈静脉使用肝素作为抗凝固剂进行采血,1小时后,以2.0ml/kg的给药量向腹腔内给予50%的四氯化碳(ナカライテクス社制造)/橄榄油(和光纯药工业社制造)。四氯化碳给药后24、48、72小时后,进行采血。将采集的血液进行离心分离,得到血浆。使用转酰酶CII-テストワコ一(和光纯药工业社制造)测定得到的血浆中的GPT活性。
图1示出大鼠血浆中的GPT活性的测定结果。四氯化碳给药后24小时后的血浆中的GPT活性与溶剂对照组相比较,在氧化型辅酶Q10给药组抑制为约60%,另外,还原型辅酶Q10给药组抑制为约25%。由此,即使在48小时后、72小时后进行观察,以溶剂对照组、氧化型辅酶Q10给药组、还原型辅酶Q10给药组的顺序血浆中的GPT活性有降低的趋势。从以上的结果可以判定,通过辅酶Q10的给药,可以抑制肝功能损害。另外还判定了还原型辅酶Q10的给药比氧化型辅酶Q10的给药可更强烈地抑制肝功能损害。
(制剂例1)
将橄榄油加温至60℃,同样加入在60℃下熔融的辅酶Q10(还原型辅酶Q10∶氧化型辅酶Q10=85∶15)并溶解。分别向其中加入少许维生素E并制成均质,通过常规方法制成软胶囊。得到1个胶囊中含有20mg辅酶Q10的软胶囊。
辅酶Q10 20重量份
维生素E 15重量份
橄榄油 350重量份
(制剂例2)
将辅酶Q10(还原型辅酶Q10∶氧化型辅酶Q10=85∶15)溶解在丙酮中,然后,将其吸附在结晶纤维素(微粉末)上之后,干燥。将其与玉米淀粉混合,通过常规方法制成散剂。
辅酶Q10 10重量份
结晶纤维素 40重量份
玉米淀粉 55重量份
(制剂例3)
将辅酶Q10(还原型辅酶Q10∶氧化型辅酶Q10=85∶15)溶解在丙酮中,然后,将其吸附在结晶纤维素(微粉末)上之后,干燥。将其与玉米淀粉、乳糖、羧甲基纤维素、硬脂酸镁混合,然后加入作为粘合剂的聚乙烯吡咯烷酮的水溶液,通过常规方法进行颗粒化。向其中加入作为润滑剂的滑石并混合后,制成每片中含有20mg的辅酶Q10的片剂。
辅酶Q10 20重量份
玉米淀粉 25重量份
乳糖 15重量份
羧甲基纤维素钙 10重量份
结晶纤维素 40重量份
聚乙烯吡咯烷酮 5重量份
硬脂酸镁 3重量份
滑石 10重量份
(制剂例4)
通过常规方法将下述成分进行颗粒化之后,填充到明胶硬胶囊中。得到1个胶囊中含有20mg辅酶Q10的胶囊剂。
辅酶Q10(还原型辅酶Q10∶氧化型辅酶Q10=85∶15) 20重量份
结晶纤维素 40重量份
玉米淀粉 20重量份
乳糖 62重量份
硬脂酸镁 2重量份
聚乙烯吡咯烷酮 3重量份
(制造例5)
将橄榄油加温到60℃,同样添加在60℃下熔融的氧化型辅酶Q10并溶解。分别向其中加入少许维生素E,并制成均质,通过常规方法制成软胶囊。得到1个胶囊中含有20mg辅酶Q10的软胶囊制剂。
氧化型辅酶Q10 20重量份
维生素E 15重量份
橄榄油 350重量份
工业实用性
按照本发明,可以提供安全性的可预防、降低肝功能损害的组合物。
Claims (22)
1.具有肝功能保护作用的组合物,其含有用下述式(1)(式中,n表示1~12的整数)表示的还原型辅酶Q
2.按照权利要求1所述的具有肝功能保护作用的组合物,其中,还原型辅酶Q是还原型辅酶Q10。
3.按照权利要求1或2所述的具有肝功能保护作用的组合物,其中,还原型辅酶Q的含量为0.001~99重量%。
4.按照权利要求1~3的任意一项所述的组合物,其还含有保健食品原料。
5.用于肝功能保护的医药制剂,其含有权利要求1~4中任意一项所述的组合物。
6.按照权利要求5所述的医药制剂,其为粉末剂或胶囊剂的形态。
7.按照权利要求5所述的医药制剂,其为饮剂、注射剂或滴注剂的形态。
8.用于肝功能保护的功能性食品,其含有权利要求1~4中任意一项所述的组合物。
9.用于肝功能保护的动物饲料,其含有权利要求1~4中任意一项所述的组合物。
10.保护哺乳动物肝功能的方法,其包括将权利要求1~4中任意一项所述的组合物对哺乳动物给药。
11.保护哺乳动物肝功能的方法,其包括向哺乳动物口服给予权利要求1~4中任意一项所述的组合物。
13.口服给药用组合物,其是权利要求12所述的具有肝功能保护作用的组合物。
14.按照权利要求12或13所述的具有肝功能保护作用的组合物,其中,氧化型辅酶Q是氧化型辅酶Q10。
15.按照权利要求12~14所述的具有肝功能保护作用的组合物,其中,氧化型辅酶Q的含量为0.001~99重量%。
16.按照权利要求12~15的任意一项所述的组合物,其还含有保健食品原料。
17.用于肝功能保护的医药制剂,其含有权利要求12~16中任意一项所述的组合物。
18.按照权利要求17所述的医药制剂,其为颗粒剂、粉末剂或胶囊剂的形态。
19.按照权利要求17所述的医药制剂,其为饮剂、注射剂或滴注剂的形态。
20.用于肝功能保护的功能性食品,其含有权利要求12~16中任意一项所述的组合物。
21.用于肝功能保护的动物饲料,其含有权利要求12~16中任意一项所述的组合物。
22.保护哺乳动物肝功能的方法,其包括向哺乳动物给予权利要求12~16中任意一项所述的组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003398485 | 2003-11-28 | ||
JP398485/2003 | 2003-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1886123A true CN1886123A (zh) | 2006-12-27 |
Family
ID=34631569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004800353794A Pending CN1886123A (zh) | 2003-11-28 | 2004-10-29 | 具有肝功能保护作用的组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070122400A1 (zh) |
EP (1) | EP1690533A4 (zh) |
JP (1) | JPWO2005051370A1 (zh) |
KR (1) | KR20060107825A (zh) |
CN (1) | CN1886123A (zh) |
AU (1) | AU2004292878A1 (zh) |
CA (1) | CA2547427A1 (zh) |
TW (1) | TW200524579A (zh) |
WO (1) | WO2005051370A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103798897A (zh) * | 2012-11-08 | 2014-05-21 | 王静 | 一种酒后调整身体状态的饮料 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006117626A (ja) * | 2004-09-24 | 2006-05-11 | Nisshin Pharma Inc | コエンザイムq10配合組成物の製造方法 |
TW200722077A (en) * | 2005-03-29 | 2007-06-16 | Kaneka Corp | Composition for enhancing expression and activity of protease in liver |
JP2007028997A (ja) * | 2005-07-27 | 2007-02-08 | Kanebo Seiyaku Kk | 生薬エキス配合流動食及びその使用 |
JP5683768B2 (ja) * | 2005-09-09 | 2015-03-11 | サントリーホールディングス株式会社 | コエンザイムq10を含有する組成物 |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
US20090098228A1 (en) * | 2007-10-10 | 2009-04-16 | Tsumura & Co. | Agent and method for improvement of impairment of learning and memory |
KR20190005471A (ko) | 2017-07-06 | 2019-01-16 | 이동원 | 가변용량 냉매 저장수단을 구비한 히트 펌프 |
KR20190005475A (ko) | 2017-07-06 | 2019-01-16 | 이동원 | 가변용량 냉매 저장수단을 구비한 고효율 히트 펌프 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3426125A (en) * | 1965-04-07 | 1969-02-04 | Yukio Shigeta | Method of treating diabetes mellitus |
JPH09187229A (ja) * | 1996-01-10 | 1997-07-22 | Idemitsu Material Kk | 家禽用飼料組成物 |
US6069167A (en) * | 1996-01-16 | 2000-05-30 | University Technology Corporation | Use of antioxidant agents to treat cholestatic liver disease |
JP3889481B2 (ja) * | 1996-08-16 | 2007-03-07 | 株式会社カネカ | 医薬組成物 |
JP3926888B2 (ja) * | 1997-05-27 | 2007-06-06 | 株式会社カネカ | コレステロール低下剤 |
IT1304406B1 (it) * | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
AU3930600A (en) * | 1999-03-30 | 2000-10-16 | Purdue Research Foundation | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof |
US6762203B2 (en) * | 1999-08-03 | 2004-07-13 | Kao Corporation | Oil composition |
WO2001026646A1 (en) * | 1999-10-08 | 2001-04-19 | Pharmnseas, Inc. | NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF |
JP3742602B2 (ja) * | 2001-05-09 | 2006-02-08 | 株式会社カネカ | 還元型補酵素qの安定な溶液 |
US20030044474A1 (en) * | 2001-08-03 | 2003-03-06 | Shaklee Corporation | High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability |
JP2003088330A (ja) * | 2001-09-14 | 2003-03-25 | Wakan Shiyouyaku Kenkyusho:Kk | ユビキノン含有栄養補助食品 |
JP5096653B2 (ja) * | 2001-09-28 | 2012-12-12 | 株式会社ペンタプラストア | 2,3−ジメトキシ−5−メチル−1,4−ジヒドロキシベンゼン誘導体およびその製造方法 |
JP3822479B2 (ja) * | 2001-10-10 | 2006-09-20 | 株式会社カネカ | 還元型補酵素q水溶液の安定化組成 |
JP2003119127A (ja) * | 2001-10-10 | 2003-04-23 | Kanegafuchi Chem Ind Co Ltd | 安定な還元型補酵素q製剤 |
TWI329513B (en) * | 2001-10-12 | 2010-09-01 | Kaneka Corp | Use of reduced coenzyme q for lessening oxidative stress |
JP2003306429A (ja) * | 2002-02-15 | 2003-10-28 | Nisshin Pharma Inc | アレルギー性疾患の予防または治療のためのコエンザイムq類を有効成分とする治療剤または飲食品 |
-
2004
- 2004-10-21 TW TW093132047A patent/TW200524579A/zh unknown
- 2004-10-29 EP EP04793405A patent/EP1690533A4/en not_active Withdrawn
- 2004-10-29 CA CA002547427A patent/CA2547427A1/en not_active Abandoned
- 2004-10-29 AU AU2004292878A patent/AU2004292878A1/en not_active Abandoned
- 2004-10-29 JP JP2005515747A patent/JPWO2005051370A1/ja active Pending
- 2004-10-29 CN CNA2004800353794A patent/CN1886123A/zh active Pending
- 2004-10-29 WO PCT/JP2004/016485 patent/WO2005051370A1/ja active Application Filing
- 2004-10-29 US US10/580,403 patent/US20070122400A1/en not_active Abandoned
- 2004-10-29 KR KR1020067012893A patent/KR20060107825A/ko not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103798897A (zh) * | 2012-11-08 | 2014-05-21 | 王静 | 一种酒后调整身体状态的饮料 |
Also Published As
Publication number | Publication date |
---|---|
EP1690533A4 (en) | 2009-03-11 |
TW200524579A (en) | 2005-08-01 |
JPWO2005051370A1 (ja) | 2007-06-14 |
US20070122400A1 (en) | 2007-05-31 |
WO2005051370A1 (ja) | 2005-06-09 |
KR20060107825A (ko) | 2006-10-16 |
CA2547427A1 (en) | 2005-06-09 |
AU2004292878A1 (en) | 2005-06-09 |
EP1690533A1 (en) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Byeon et al. | Recent formulation approaches to oral delivery of herbal medicines | |
TWI759260B (zh) | 多元補充品組成物 | |
US5547671A (en) | Anti-intoxication composition | |
CN109568538B (zh) | 包含水飞蓟、姜黄、甘草以及决明子的宿醉消解用组合物 | |
CN1886123A (zh) | 具有肝功能保护作用的组合物 | |
US8440219B2 (en) | Reduced-odor thiol compositions | |
CN105934161A (zh) | 含有油性的,辛辣的,有气味的物质的组合物和其制备方法 | |
KR101192280B1 (ko) | 참당귀 열수 추출물의 나노입자화를 이용한 소아용 면역 증진용 캔디류 제조방법 및 그 캔디 | |
CN102068480A (zh) | 一种清暑解毒的食药两用复方制剂 | |
WO2014010656A1 (ja) | 優れた血中アルコール濃度低下促進剤 | |
TW200526193A (en) | Anti-aging composition | |
CN1255138C (zh) | 一种对酒精性肝损伤具有辅助保护作用的中药制剂及制备方法 | |
JP2007126410A (ja) | 肝疾患予防及び治療用生薬組成 | |
JP6762946B2 (ja) | バーンアウト症候群の予防、改善、または治療用組成物 | |
EP1520584A1 (en) | Composition for the activation of the immune system | |
KR101102801B1 (ko) | 의약 조성물 | |
JP2007014281A (ja) | 噴霧摂取可能な液状食品組成物及びその製造方法 | |
CA2639895A1 (en) | Energizing compositions comprising goji, red clover and polygonum multiflorum, and uses thereof | |
JP7162357B2 (ja) | 桂皮酸誘導体の吸収促進剤 | |
US11878007B1 (en) | Metabolism enhancing compositions | |
ES2343119T3 (es) | Composicion para la activacion del sistema inmune. | |
KR100977583B1 (ko) | 불미나리에서 간세포 보호 및 간손상 예방 효능을 갖는카페익산을 추출하는 방법 및 이를 포함하는 기능성건강지향식품 | |
JP7471651B2 (ja) | ソフトカプセル集合体及びこれを含む経口投与用組成物 | |
CN105998731B (zh) | 一种辅助实现中长跑运动员超量恢复的虫草超微粉胶囊 | |
CN106880599B (zh) | 含多单位载体的固态软式口溶锭 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |